Form 4: Pharvaris CCO Wim Souverijns Executes Stock Sale

Chief Commercial Officer Wim Souverijns sold 10,000 shares of Pharvaris N.V. common stock via a pre-arranged 10b5-1 trading plan.

Summary

• Wim Souverijns, Chief Commercial Officer of Pharvaris N.V., sold 10,000 shares of common stock on May 15, 2026.
• The shares were sold at a weighted average price of $29.9163 per share.
• The transaction was executed pursuant to a Rule 10b5-1 trading plan, which allows insiders to set up a predetermined schedule for selling stocks.
• Following the transaction, the reporting person retains beneficial ownership of 45,111 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed through a pre-planned 10b5-1 mechanism, which is a standard administrative action for executives.

Positives

• The sale was conducted under a pre-established 10b5-1 trading plan, indicating the transaction was scheduled in advance rather than based on non-public information.

Negatives

• The sale represents a reduction in the insider's direct equity stake in the company.

Risks

• Insider selling can sometimes be perceived by the market as a lack of confidence in future share price appreciation, though 10b5-1 plans are designed to mitigate this perception.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Management Comments

• The reporting person confirmed the sale was executed pursuant to a Rule 10b5-1 trading plan.

Industry Context

StockSavvy.ai notes that routine insider selling via 10b5-1 plans is a standard practice for corporate executives to manage personal liquidity and is generally viewed as neutral by the investment community.

Comparison to Industry Standards

• The use of 10b5-1 plans is the industry standard for executives to avoid potential conflicts of interest or accusations of insider trading.

Stakeholder Impact

• Minimal impact expected as the sale was pre-planned and represents a small portion of the executive's total holdings.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Pharvaris, PHVS, Insider Trading, Form 4, Wim Souverijns, Biotech, 10b5-1